tbuckley/cabot-search huggingface dataset:
A partial human LCK defect causes a T cell immunodeficiency with intestinal inflammation
Authors: Victor G. Lui, Manfred Hoenig, Berenice Cabrera-Martinez, Ryan M. Baxter, Josselyn E. Garcia-Perez, Olivia Bailey, Atanu Acharya, Karl Lundquist, Jesusa Capera, Paul Matusewicz, Frederike A. Hartl, Marco D’Abramo, Josephine Alba, Eva-Maria Jacobsen, Doris Niewolik, Myriam Lorenz, Ulrich Pannicke, Ansgar S. Schulz, Klaus-Michael Debatin, Wolfgang W. Schamel, Susana Minguet, James C. Gumbart, Michael L. Dustin, John C. Cambier, Klaus Schwarz, Elena W.Y. Hsieh
Journal: The Journal of Experimental Medicine (2023)

Lymphocyte-specific protein tyrosine kinase (LCK) is essential for T cell antigen receptor (TCR)–mediated signal transduction. Here, we report two siblings homozygous for a novel LCK variant (c.1318C&amp;gt;T; P440S) characterized by T cell lymphopenia with skewed memory phenotype, infant-onset recurrent infections, failure to thrive, and protracted diarrhea. The patients’ T cells show residual TCR signal transduction and proliferation following anti-CD3/CD28 and phytohemagglutinin (PHA) stimulation. We demonstrate in mouse models that complete (Lck−/−) versus partial (LckP440S/P440S) loss-of-function LCK causes disease with differing phenotypes. While both Lck−/− and LckP440S/P440S mice exhibit arrested thymic T cell development and profound T cell lymphopenia, only LckP440S/P440S mice show residual T cell proliferation, cytokine production, and intestinal inflammation. Furthermore, the intestinal disease in the LckP440S/P440S mice is prevented by CD4+ T cell depletion or regulatory T cell transfer. These findings demonstrate that P440S LCK spares sufficient T cell function to allow the maturation of some conventional T cells but not regulatory T cells—leading to intestinal inflammation.
O13-3 Subcutaneous epcoritamab in Japanese patients with relapsed/refractory diffuse large B-cell lymphoma: EPCORE NHL-3 data
Authors: Koji Izutsu, Takahiro Kumode, Junichiro Yuda, Hirokazu Nagai, Yuko Mishima, Youko Suehiro, Kazuhito Yamamoto, Tomoaki Fujisaki, Kenji Ishitsuka, Kenichi Ishizawa, Takayuki Ikezoe, Momoko Nishikori, Daigo Akahane, Jiro Fujita, Jun Wu, Per Broberg, Jeppe Buchbjerg, Noriko Fukuhara
Journal: Annals of Oncology (2023)

Epcoritamab, a subcutaneously (SC) administered CD3xCD20 bispecific antibody, has shown deep, durable antitumor activity and manageable safety in patients (pts) with B-cell non-Hodgkin lymphomas (EHA 2022, abstract LB2364). We present data from arm 1 of the EPCORE NHL-3 phase 1/2 trial (NCT04542824) evaluating epcoritamab monotherapy in Japanese pts with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL). Pts with R/R CD20+ DLBCL received SC epcoritamab 48 mg in 28-d cycles (QW, cycle [C] 1–3; Q2W, C4–9; Q4W, C≥10) until disease progression or unacceptable toxicity. Step-up dosing (day [D] 1, 0.16 mg; D8, 0.8 mg; D15, 48 mg) and corticosteroids were required in C1 for CRS mitigation. As of January 31, 2022, 36 pts with R/R DLBCL (median age, 69 y) had received epcoritamab. The median number of prior treatment (Tx) lines was 3 (range, 2–8); 56% had primary refractory disease and 81% were refractory to their last Tx line. Tx was ongoing in 14/36 (39%) pts, with a median follow-up of 8.4 mo (range, 1.5+ to 12.0). CRS (83%), injection-site reactions (58%), decreased neutrophil count (36%), hypokalemia (28%), and decreased lymphocyte count (25%) were the most common Tx-emergent AEs. Most CRS events occurred following the first full dose on C1D15 and were low grade (grade [G] 1, 18 pts; G2, 9 pts; G3, 3 pts; no G4–5); 10 pts received tocilizumab. All CRS events resolved (median time to resolution, 5 d); no pts discontinued Tx due to CRS. The 1 ICANS event (G1) resolved. Among 36 efficacy-evaluable pts, overall response rate and complete metabolic response rate (independent review committee, Lugano 2014) were 56% and 44%, respectively. Median duration of response and median overall survival were not reached. SC epcoritamab showed high response rates and a manageable safety profile in Japanese pts with highly refractory and heavily pretreated disease, supporting further evaluation of epcoritamab in pts with R/R DLBCL.
O3-4 Umbrella reviews of systematic reviews assessing pelvic floor muscle training on post-radical prostatectomy incontinence
Authors: Wan-Shiuan Lin, Yuan-Hao Yang
Journal: Annals of Oncology (2023)

A well-designed program is one of the reasons for the efficacy of pelvic floor muscle training (PFMT). The study aims to evaluate the content of PFMT programs on urinary incontinence after radical prostatectomy (RP) using an umbrella review approach in adult patients with prostate cancer. The was an umbrella review of systematic reviews of randomized controlled trials (RCTs). A comprehensive search was conducted to screen eligible studies, which were identified from Cochrane Library, Joanna Briggs Institute, Pubmed, MEDLINE, and SCOPUS databases science inception to July 2022. Two reviewers independently screened the titles and abstracts of retrieved articles, and they extracted data. Key outcomes were assessed by the Critical Appraisal Skills Programme (CASP) checklists. It was necessary to resolve any disagreements by discussing. Three systematic reviews of RCTs included a total of 29 RCTs and 4,090 patients. The sample size varied from 32 to 788 patients included in the review. PFMT which commenced within 6 weeks postoperatively, improved postoperative continence rate and the quality of life significantly compared to those patients receiving standard care. PFMT which commenced 4 weeks preoperatively, improved early continence after RP significantly compared to those patients receiving standard care. These exercise intervention significantly reduces continence recovery time. Effective PFMT is carried out with a duration of 10-45 minutes per day with 10 contractions in a lying, sitting, and standing position with three sets, time of contractions 5-10 seconds, and relaxation 5-10 seconds. PFMT is suitable, well-accepted, and achievable for patients who experience incontinence after radical prostatectomy. Standardized and physiotherapist-guided clinical trials are wanted for further studies.
O10-2 Telisotuzumab vedotin monotherapy in Asian patients with c-Met–overexpressing advanced non-small cell lung cancer
Authors: Hidehito Horinouchi, D. Ross Camidge, Jair Bar, Jonathan Goldman, Fedor Moiseenko, Elena Filippova, Irfan Cicin, Penelope Bradbury, Nathalie Daaboul, Pascale Tomasini, Tudor Ciuleanu, David Planchard, Mor Moskovitz, Nicolas Girard, Martin Dunbar, Ellen Bolotin, Jim Looman, Christine Ratajczak, Shun Lu
Journal: Annals of Oncology (2023)
O7-3 Phase II study of brigatinib in patients with TKI-naive ROS1-rearranged non-small cell lung cancer (NSCLC): Barossa study
Authors: Toshiaki Takahashi, Seiji Niho, Ryo Toyozawa, Yasushi Goto, Kadoaki Ohashi, Haruko Daga, Hiroshi Tanaka, Yoshihiro Hattori, Masahiro Morise, Jun Sakakibara-Konishi, Masahiro Kodani, Takaya Ikeda, Shingo Matsumoto, Kiyotaka Yoh, Shogo Nomura, Koichi Goto
Journal: Annals of Oncology (2023)
O13-4 2-year update of KTE-X19 in adults with relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) in ZUMA-3
Authors: Bijal D. Shah, Armin Ghobadi, Olalekan O. Oluwole, Aaron C. Logan, Nicolas Boissel, Ryan D. Cassaday, Edouard Forcade, Michael R. Bishop, Max S. Topp, Dimitrios Tzachanis, Kristen M. O'Dwyer, Martha L. Arellano, Yi Lin, Maria R. Baer, Gary J. Schiller, Lang Zhou, Petra C. Schuberth, Behzad Kharabi Masouleh, Roch Houot
Journal: Annals of Oncology (2023)
O16-3 Extending adjuvant temozolomide may increase risk of adverse events while conferring no survival benefits in glioblastoma patients
Authors: Arthur Chak Kai Lau, Man Toi Chiu, Brandon Lok Hang Chan, Peter Yat Ming Woo
Journal: Annals of Oncology (2023)

Standard-of-care for glioblastoma after surgery consists of concurrent chemoradiation (CCRT) followed by 6 cycles of adjuvant-phase temozolomide (adjTMZ). This study investigates the association between extending adjTMZ beyond 6 cycles and OS and PFS, as well as hematological derangements and clinical adverse events in glioblastoma patients. This was a multicenter retrospective study of 126 propensity-score matched adult patients with glioblastoma treated with surgery and CCRT in Hong Kong, 2005-2020. Propensity score matching was used to match patients receiving >6 cycles adjTMZ with those who had 6 cycles in a 1:2 ratio. OS and PFS were compared with multivariate Cox regression, adjusting for important predictors including age, sex, preoperative Karnofsky performance status, MGMT methylation status and extent of resection. Incidences of 7 hematological derangements and 18 clinical adverse events were compared. Extending adjTMZ brought no significant benefit in OS (p=0.89) or PFS (p=0.76). However, extended-TMZ group saw significantly higher rates of leukopenia (p = 0.04), thrombocytopenia (p = 0.01), lymphocytopenia (p = 0.04) and deranged ALT (p = 0.02); but little differences for anaemia (p=0.45), neutropenia (p=1.00) and ALP (p=0.31). Lung infection (p=0.04) and seizures (p=0.05) were also significantly more frequent in the extended-TMZ group. Our study found that extended adjTMZ was associated with significantly higher rates of certain hematological derangements and clinical adverse events, but conferred no survival benefit in glioblastoma patients. Thus, our findings did not support a routine practice of extending adjTMZ beyond six cycles for adult glioblastoma patients.
O5-1 Reliability and validity of the Japanese version of the Chemotherapy-induced Alopecia Distress Scale
Authors: Yosuke Aoyama, Eri Hoshino, Akihiko Shimomura, Juhee Cho, Chikako Shimizu, Tomoko Taniyama, Manami Tada, Nao Yoshida, Kazumasa Yamamoto, Rika Kizawa, Takeshi Yamaguchi, Kiyo Tanaka, Yoko Kobayashi, Nobuko Tamura, Yuko Tanabe, Koichi Suyama, Yuji Miura, Kojiro Shimozuma, Hidetaka Kawabata
Journal: Annals of Oncology (2023)
O7-4 Phase 1b efficacy of telisotuzumab vedotin and osimertinib in Asian vs non-Asian patients with advanced NSCLC
Authors: Hidehito Horinouchi, Jonathan Goldman, Byoung Chul Cho, Pascale Tomasini, Martin Dunbar, David Hoffman, Apurvasena Parikh, Vincent Blot, D. Ross Camidge
Journal: Annals of Oncology (2023)
O9-1 Paclitaxel plus cetuximab vs. nivolumab for patients with platinum-refractory recurrent/metastatic head and neck cancer
Authors: Hiroyuki Kodama, Shigenori Kadowaki, Munehiro Wakabayashi, Akinobu Nakata, Ryosuke Kumanishi, Taeko Nakazawa, Takatsugu Ogata, Yuki Matsubara, Kazunori Honda, Toshiki Masuishi, Yukiya Narita, Hiroya Tanigichi, Masashi Ando, Nobuhiro Hanai, Kei Muro
Journal: Annals of Oncology (2023)
O6-4 Clinicoimmunological study of sarcomatoid carcinoma across organs
Authors: Ryo Morisue, Motohiro Kojima, Toshihiro Suzuki, Tetsuya Nakatsura, Naoto Gotohda, Shumpei Ishikawa
Journal: Annals of Oncology (2023)

The efficacy of immunotherapy against sarcomatoid carcinoma (SC) and the tumor immune microenvironment (TME) with rich tumor-infiltrating lymphocytes have been reported in various organs, suggesting TME features of SC may be common beyond organs. We aimed to elucidate the clinicoimmunological features of SC across the organ. Subjects were primary SCs resected at our hospital (1997-2020); controls were equal numbers of typical cancers (non-SC) in each organ adjusted for stage (UICC-8th). Clinicopathological analysis and comparison of tumor-infiltrating CD8+ T cell density and tumor PD-L1 expression score (TPS) by multiplex immunostaining were performed. Nominal variables are shown as frequency and continuous variables as a median. A total of 101 patients (31 lung, 19 esophagus, 22 pancreas, 15 liver, 4 biliary tract, 6 kidney, 2 uterus, and 2 ovary) were included in the study, and the same number of non-SC were extracted in each organ. Clinicopathological analysis revealed no significant differences in age (non-SC vs. SC [in that order], 68 vs 69 years), male (70 vs 79%), nodal metastasis (44 vs 47%), and distant metastasis (8 vs 9%), but tumor size was significantly larger in SC (41 vs 52 mm, p=0.014). Prognostic analysis showed significantly shorter overall survival (55.2 vs 27.5 months, p=0.004) and progression-free survival in SC patients than in non-SC patients (21.3 vs. 9.5 months, p=0.008), and a significantly higher rate of progression within 6 months (28 vs 54%, p=0.002). Of 73 SC patients with postoperative progression, those treated with immunotherapy (n=5) had a significantly longer survival after progression than those without (62.8 vs 9.2 months, p=0.040). TME analysis showed higher CD8+ T cell density in SC than non-SC (p=0.004), and TPS was significantly higher in SC (p<0.001). SC showed aggressive biology but responded to immunotherapy, underlying TME with abundant tumor-infiltrating CD8+ T cells and high tumor PD-L1 expression.
O15-3 Nivolumab plus ipilimumab (N+I) for potentially resectable hepatocellular carcinoma (HCC): Efficacy and surgical outcome
Authors: Yung-Yeh Su, Yih-Jyh Lin, Chin-Fu Hsiao, Da-Liang Ou, San-Chi Chen, Hung-Wei Wang, Jing-Houng Wang, Yao-Ming Wu, Wei-Chen Lee, Shu-Cheng Chou, Ching-Liang Ho, Chang-Fang Chiu, Li-Tzong Chen, Yen-Shan Shen, Ann-Lii Cheng, Chiun Hsu
Journal: Annals of Oncology (2023)
O6-3 Interim results of FIH phase 1 of TAK-102, GPC-3 targeted armored CAR-T therapy in patients with advanced solid tumors
Authors: Yasutoshi Kuboki, Toshio Shimizu, Toshihiko Doi, Noboru Yamamoto, Shunsuke Kondo, Abood Okal, Aman Singh, Janet Markman, Takenori Akaike, Hideaki Kagehara, Takafumi Koyama
Journal: Annals of Oncology (2023)
O5-3 Expert training workshop on support for balancing cancer treatment and work organized by West Japan Oncology Group
Authors: Satoshi Ikeda, Yuichi Ozawa, Michitaka Nagase, Kenjiro Aogi, Koji Onishi, Etsuko Hosoda, Seiichiro Tateishi, Miyako Takahashi, Toshiyuki Sawa
Journal: Annals of Oncology (2023)
O14-1 A randomized phase II study comparing S-1 plus oxaliplatin with S-1 monotherapy for elderly patients with advanced gastric cancer: WJOG8315G
Authors: Akitaka Makiyama, Hirokazu Shoji, Hisato Kawakami, Takao Tamura, Keiji Sugiyama, Hiroki Hara, Michitaka Nagase, Kazuo Nishikawa, Taito Esaki, Naoki Izawa, Masato Nakamura, Takayuki Ando, Yuji Miura, Yukiya Narita, Mototsugu Shimokawa, Kentaro Yamazaki, Shuichi Hironaka, Ichinosuke Hyodo, Kei Muro
Journal: Annals of Oncology (2023)

Because of various vulnerabilities of elderly patients (EP), therapeutic development referring to geriatric assessment (GA) is required. We conducted a randomized trial comparing S-1 plus oxaliplatin (SOX) with S-1 for EP with advanced gastric cancer (AGC). EP aged ≥70 years with HER2-negative AGC, no prior chemotherapy, creatinine clearance ≥30 mL/min and PS ≤2 were randomized to receive S-1 (50-120 mg/body, day 1-28, q6w) or SOX (S-1 same dose, day 1-14 + oxaliplatin, 100 mg/m2, on day 1, q3w). Pretreatment GA was performed using G8. The primary endpoint was overall survival (OS). Secondary endpoints included progression-free survival (PFS), response rate (RR) and safety. Exploratorily, the relationships between G8 scores and efficacies were analyzed. OS events of 121 were required to achieve 75% power with one-sided alpha error of 20%, expecting the median OS of the S-1 and SOX arms would be 11.0 and 14.5 months, respectively. From April 2016 to August 2020, 160 EP (80 each in S-1 and SOX) were enrolled. Median OS was 13.0 and 16.2 months (HR=0.73, 60% CI 0.63-0.84, p=0.0535), and median PFS was 3.6 and 6.5 months (HR=0.56, 95% CI 0.49-0.65, p=0.0004) in the S-1 and SOX arms, associated with response rates of 35.0 and 68.6%, respectively. The incidence of grade ≥3 adverse events did not differ between the two arms, while grade ≥2 neutropenia (25.3% vs 57.0%), thrombocytopenia (7.6% vs 24.1%) and peripheral sensory neuropathy (0% vs 26.6%) were observed more frequently in the SOX arm than the S-1 arm. In the subset analysis according to the G8 score (median value, 11), superiority of SOX in OS was not seen in EP with G8 score ≤11 (HR = 1.06, 95% CI 0.64-1.74). Survival superiority of SOX over S-1 alone was suggested with acceptable safety in EP with AGC, and the survival benefit seemed to depend on the vulnerability measured by G8.
O16-4 A phase 2 trial of nivolumab monotherapy in rare cancer patients with mismatch repair deficiency or MSI-high: ROCK trial (NCCH1709) from MASTER KEY Project
Authors: Kenji Tsuchihashi, Hitomi Okuma, Ryunosuke Machida, Ryo Sadachi, Akihiro Hirakawa, Hiroshi Ariyama, Masafumi Kanai, Natsuko Okita, Kenichi Nakamura, Kan Yonemori
Journal: Annals of Oncology (2023)
O7-2 A phase II study to assess the efficacy of osimertinib in patients with EGFR MT(+)T790M(-) NSCLC
Authors: Daisuke Hayakawa, Masayuki Takeda, Mototsugu Shimokawa, Atsushi Nakamura, Kaname Nosaki, Yasutaka Watanabe, Terufumi Kato, Hiroshi Tanaka, Toshiaki Takahashi, Masahide Oki, Motoko Tachihara, Daichi Fujimoto, Kakuhiro Yamaguchi, Hidetoshi Hayashi, Shoichiro Yamamoto, Eiji Iwama, Koichi Azuma, Nobuyuki Yamamoto, Kazuhiko Nakagawa
Journal: Annals of Oncology (2023)
O9-2 Salvage chemotherapy with paclitaxel plus cetuximab (PE)-based regimen following immune checkpoint inhibitor in R/M SCCHN
Authors: Hideki Tanaka, Tomohiro Enokida, Susumu Okano, Yuri Ueda, Takao Fujisawa, Akihisa Wada, Masanobu Sato, Naohiro Takeshita, Nobukazu Tanaka, Ryutoro Onaga, Yuta Hoshi, Makoto Tahara
Journal: Annals of Oncology (2023)
Reimagining Thriving Ethics Programs without Ethics Committees
Authors: Hilary Mabel, Joshua S. Crites, Thomas V. Cunningham, Jordan Potter
Journal: The American Journal of Bioethics (2023)

With the increasing professionalization of clinical ethics, some hospitals and health systems utilize both ethics committees and professional clinical ethicists to address their ethics needs. Drawing upon historical critiques of ethics committees and their own experiences, the authors argue that, in ethics programs with one or more professional clinical ethicists, ethics committees should be dissolved when they fail to meet minimum standards of effectiveness. The authors outline several criteria for assessing effectiveness, describe the benefits of a model that places primary responsibility for ethics work with professional clinical ethicists-the PCE-primary model, and offer suggestions for alternative ethics program structures that empower healthcare professionals to contribute to ethics work in ways more tailored to their strengths and skills while minimizing the shortcomings of ethics committees.
Unravelling the respiratory health path across the lifespan for survivors of preterm birth
Authors: Shannon J Simpson, Cassidy Du Berry, Denby J Evans, James T D Gibbons, Maria Vollsæter, Thomas Halvorsen, Karl Gruber, Enrico Lombardi, Sanja Stanojevic, John R Hurst, Petra Um-Bergström, Jenny Hallberg, Lex W Doyle, Sailesh Kotecha
Journal: The Lancet Respiratory Medicine (2023)
Sexual and Moral Harassment of French Urologists in Training and Barriers to Reporting: Results from a National Survey
Authors: Emilien Seizilles de Mazancourt, Juliette Cotte, Caroline Plassais, Ugo Pinar, Anna Goujon, Fayek Taha, Denis Seguier, Truong An Nguyen, Francois Lannes, Claire Deleuze, Florian Bardet, Kevin Kaulanjan
Journal: European Urology (2023)
Consumption of ultra-processed foods and risk of multimorbidity of cancer and cardiometabolic diseases: a multinational cohort study
Authors: Reynalda Cordova, Vivian Viallon, Emma Fontvieille, Laia Peruchet-Noray, Anna Jansana, Karl-Heinz Wagner, Cecilie Kyrø, Anne Tjønneland, Verena Katzke, Rashmita Bajracharya, Matthias B. Schulze, Giovanna Masala, Sabina Sieri, Salvatore Panico, Fulvio Ricceri, Rosario Tumino, Jolanda M.A. Boer, W.M.Monique Verschuren, Yvonne T. van der Schouw, Paula Jakszyn, Daniel Redondo-Sánchez, Pilar Amiano, José María Huerta, Marcela Guevara, Yan Borné, Emily Sonestedt, Konstantinos K. Tsilidis, Christopher Millett, Alicia K. Heath, Elom K. Aglago, Dagfinn Aune, Marc J. Gunter, Pietro Ferrari, Inge Huybrechts, Heinz Freisling
Journal: The Lancet Regional Health - Europe (2023)

It is currently unknown whether ultra-processed foods (UPFs) consumption is associated with a higher incidence of multimorbidity. We examined the relationship of total and subgroup consumption of UPFs with the risk of multimorbidity defined as the co-occurrence of at least two chronic diseases in an individual among first cancer at any site, cardiovascular disease, and type 2 diabetes.
Primary antibiotic resistance of Helicobacter pylori in the Asia-Pacific region between 1990 and 2022: an updated systematic review and meta-analysis
Authors: Tzu-Chan Hong, Emad M El-Omar, Yu-Ting Kuo, Jeng-Yih Wu, Mei-Jyh Chen, Chieh-Chang Chen, Yu-Jen Fang, Alex Hwong Ruey Leow, Hong Lu, Jaw-Town Lin, Yu-Kang Tu, Yoshio Yamaoka, Ming-Shiang Wu, Jyh-Ming Liou, Tzu-Chan Hong, Emad M El-Omar, Yu-Ting Kuo, Jeng-Yih Wu, Mei-Jyh Chen, Chieh-Chang Chen, Yu-Jen Fang, Alex Hwong Ruey Leow, Hong Lu, Jaw-Town Lin, Yu-Kang Tu, Yoshio Yamaoka, Ming-Shiang Wu, Jyh-Ming Liou, Yi-Chu Chen, Yung-Yueh Chang
Journal: The Lancet. Gastroenterology & hepatology (2023)
Sex-related differences in patient characteristics, and efficacy and safety of advanced therapies in randomised clinical trials in psoriatic arthritis: a systematic literature review and meta-analysis
Authors: Lihi Eder, Sivakami Mylvaganam, Jordi Pardo Pardo, Jennifer Petkovic, Vibeke Strand, Philip Mease, Keith Colaco
Journal: The Lancet Rheumatology (2023)
Treatment of severe symptomatic aortic valve stenosis using non-invasive ultrasound therapy: a cohort study
Authors: Emmanuel Messas, Alexander Ijsselmuiden, Danijela Trifunović-Zamaklar, Bernard Cholley, Etienne Puymirat, Jonathan Halim, Radmila Karan, Menno van Gameren, Duško Terzić, Vladimir Milićević, Mickael Tanter, Mathieu Pernot, Guillaume Goudot
Journal: The Lancet (2023)
Development and validation of age-specific risk prediction models for primary ovarian insufficiency in long-term survivors of childhood cancer: a report from the Childhood Cancer Survivor Study and St Jude Lifetime Cohort
Authors: Cindy Im, Zhe Lu, Sogol Mostoufi-Moab, Angela Delaney, Lin Yu, Jessica L Baedke, Yutong Han, Yadav Sapkota, Yutaka Yasui, Eric J Chow, Rebecca M Howell, Smita Bhatia, Melissa M Hudson, Kirsten K Ness, Gregory T Armstrong, Paul C Nathan, Yan Yuan
Journal: The Lancet Oncology (2023)